奥美医疗用品股份有限公司 章程 （2025 年 10 月） — 1 — | 第一章 | 总则 | | 3 | | --- | --- | --- | --- | | 第二章 | | 经营宗旨和范围 | 4 | | 第三章 | 股份 | | 6 | | 第一节 | | 股份发行 | 6 | | 第二节 | | 股份增减和回购 | 7 | | 第三节 | | 股份转让 | 9 | | 第四章 | | 股东和股东会 | 10 | | 第一节 | | 股东的一般规定 | 10 | | 第二节 | | 控股股东和实际控制人 | 14 | | 第三节 | | 股东会的一般规定 | 15 | | 第四节 | | 股东会的召集 | 19 | | 第五节 | | 股东会的提案与通知 | 21 | | 第六节 | | 股东会的召开 | 23 | | 第七节 | | 股东会的表决和决议 | 26 | | 第五章 | 董事会 | | 31 | | 第一节 | | 董事 | 31 | | 第二节 | | 董事会 | 36 | | 第三节 | | 独立董事 | 45 | | 第四节 | | 董事会专门委员会 | 49 | | 第六章 | ...

证券代码：002950 证券简称：奥美医疗 公告编号：2025-061 奥美医疗用品股份有限公司 关于完成工商变更登记的公告 公司于近日取得了宜昌市市场监督管理局出具的《登记通知书》，公司工商 变更登记及公司章程备案等手续已完成。核准后的公司章程请见同日在巨潮资 讯网（http://www.cninfo.com.cn）上披露的《公司章程（2025 年 10 月）》。 三、备查文件 宜昌市市场监督管理局出具的《登记通知书》。 特此公告。 奥美医疗用品股份有限公司 董事会 2025 年 12 月 9 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、基本情况 奥美医疗用品股份有限公司（以下简称"公司"）分别于 2025 年 10 月 24 日、2025 年 11 月 11 日召开第三届董事会第十六次会议、2025 年第一次临时 股东大会，审议通过《关于审议公司修订<公司章程>及相关制度的议案》《选 举第四届董事会非独立董事的议案》《选举第四届董事会独立董事的议案》。公 司根据《公司法》《上市公司章程指引》等法律法规、规范性文件的规定，结合 公司实际情况，完成 ...

Core Viewpoint - Aomei Medical (002950.SZ) has announced a share buyback program, indicating a strategic move to enhance shareholder value through repurchase of shares [1] Group 1: Share Buyback Details - The company has repurchased a total of 5,306,200 shares, which represents 0.8379% of its current total share capital [1] - The highest transaction price for the repurchased shares was 10.05 CNY per share, while the lowest was 8.33 CNY per share [1] - The total amount paid for the share buyback was 50,618,607.00 CNY, excluding transaction fees such as stamp duty and commissions [1]

Group 1 - The core point of the article is that Aomei Medical has announced a share buyback plan, repurchasing approximately 5.31 million shares, which represents 0.8379% of its total share capital, with a total expenditure of about 50.62 million yuan [1][1][1] - The highest transaction price during the buyback was 10.05 yuan per share, while the lowest was 8.33 yuan per share [1][1][1] - As of the report, Aomei Medical's market capitalization stands at 7.4 billion yuan [1][1][1] Group 2 - For the first half of 2025, Aomei Medical's revenue composition shows that medical devices account for 94.13% of total revenue, while other segments contribute 5.87% [1][1][1]

证券代码：002950 证券简称：奥美医疗 公告编号：2025-060 奥美医疗用品股份有限公司 截至 2025 年 11 月 30 日，公司累计通过深圳证券交易所交易系统以集中竞价交易方 式回购公司股份 5,306,200 股，占公司目前总股本的比例为 0.8379%，最高成交价为 10.05 元/股，最低成交价为 8.33 元/股，支付的总金额为 50,618,607.00 元（不含印花税、 交易佣金等交易费用）。 二、其他说明 截至目前，本次回购实施情况与回购股份方案不存在差异。公司后续将根据市场情况 在回购期限内实施本次回购计划，并按照相关法律法规的规定及时履行信息披露义务。敬 请广大投资者关注后续公告，并注意投资风险。 特此公告。 奥美医疗用品股份有限公司 董事会 2025 年 12 月 2 日 关于股份回购进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 奥美医疗用品股份有限公司（以下简称"公司"）董事会于 2025 年 1 月 20 日召开第 三届董事会第十二次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议 案》，同意公司 ...

Core Viewpoint - Aomei Medical has shown a significant stock price increase of 30.78% year-to-date, despite a recent decline of 5.66% over the last five trading days, indicating volatility in its stock performance [1][2]. Financial Performance - For the period from January to September 2025, Aomei Medical reported a revenue of 2.597 billion yuan, representing a year-on-year growth of 5.98% [2]. - The net profit attributable to shareholders for the same period was 349 million yuan, reflecting a substantial year-on-year increase of 31.54% [2]. Stock Market Activity - As of November 25, Aomei Medical's stock price was 11.34 yuan per share, with a market capitalization of 7.181 billion yuan [1]. - The stock experienced a trading volume of 48.9651 million yuan, with a turnover rate of 0.96% [1]. - The net inflow of main funds was 2.4763 million yuan, with large orders accounting for 13.00% of purchases and 7.94% of sales [1]. Shareholder Information - As of September 30, 2025, Aomei Medical had 37,800 shareholders, an increase of 0.71% from the previous period [2]. - The average number of circulating shares per shareholder was 11,965, which decreased by 0.71% [2]. - The company has distributed a total of 1.099 billion yuan in dividends since its A-share listing, with 91.9131 million yuan distributed over the last three years [3]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fifth-largest circulating shareholder, holding 17.9166 million shares, an increase of 5.5221 million shares from the previous period [3]. - The Medical Device ETF (159883) was noted as a new tenth-largest circulating shareholder, holding 1.5656 million shares [3].

Core Viewpoint - Aomei Medical (002950) has transitioned from "manufacturing" to "quality manufacturing" and then to "intelligent manufacturing," enhancing its competitive advantage through technological integration [1] Group 1: Company Development - Aomei Medical is recognized as a global leader in the production of medical dressings and infection protection products [1] - The company has implemented multiple technological upgrades in recent years to improve production efficiency [1] Group 2: Product Innovation - Aomei Medical has continuously launched functional dressing products and medical care pads, receiving positive feedback from patients and consumers [1] - The company aims to deepen its focus on product manufacturing and development to strengthen its market competitiveness [1]

Core Viewpoint - Aomei Medical (002950) has made significant advancements in the fields of surgical and wound care, infection protection, advanced dressings, and hygiene products, focusing on enhancing its competitive edge through technological integration [1] Group 1: Product Development and Innovation - The company has transitioned from "manufacturing" to "quality manufacturing" and then to "intelligent manufacturing," aiming to elevate its competitive advantage to a technological integration level [1] - Aomei Medical has implemented multiple technological upgrades in recent years to improve production efficiency [1] - The company continues to launch functional dressing products and medical care pads, which have received positive feedback from patients and consumers [1] Group 2: Market Strategy - Aomei Medical is committed to deepening its focus on product manufacturing and development to further strengthen its market competitiveness [1]

Core Viewpoint - The company, Aomei Medical, is a leading global manufacturer of medical dressings and infection protection products, emphasizing the importance of functional dressings in its product lineup [1] Product Overview - Aomei Medical has launched several types of functional dressings, including hydrophilic fiber dressings, soft silicone foam dressings, hydrocolloid dressings, transparent dressings, and silicone gel scar patches [1] - These products are widely applicable for various acute and chronic wound care scenarios, particularly benefiting patients with chronic wounds such as venous ulcers, diabetic ulcers, traumatic ulcers, and pressure ulcers [1] - The company holds a leading position in the industry regarding these functional dressing products [1]

Core Viewpoint - The company, Aomei Medical, is a leading global manufacturer of medical dressings and infection protection products, emphasizing the importance of functional dressings in its product lineup [1] Product Overview - Aomei Medical has launched several types of functional dressings, including hydrophilic fiber dressings, soft silicone foam dressings, hydrocolloid dressings, transparent dressings, and silicone gel scar patches [1] - These products are widely applicable for various acute and chronic wound care scenarios, particularly benefiting patients with chronic wounds such as venous ulcers, diabetic ulcers, traumatic ulcers, and pressure ulcers [1] - The company holds a leading position in the industry regarding these functional dressing products [1]